A drug-likeness toolbox facilitates ADMET study in drug discovery.

By Chen-Yang Jia, Jing-Yi Li, Ge-Fei Hao, Guangfu Yang. Drug Discovery Today, 2019

473 citations recorded by the source corpus.

Undesirable pharmacokinetic (PK) properties or unacceptable toxicity are the main causes of the failure of drug candidates at the clinical trial stage. Since the concept of drug-likeness was first proposed, it has become an important consideration in the selection of compounds with desirable bioavailability during the early phases of drug discovery. Over the past decade, online resources have effectively facilitated drug-likeness studies in an economical and time-efficient manner. Here, we provide a comprehensive summary and comparison of current accessible online resources, in terms of their key features, application fields, and performance for in silico drug-likeness studies. We hope that the assembled toolbox will provide useful guidance to facilitate future in silico drug-likeness research.

Subfields: Biomedical Engineering, Computational Theory and Mathematics, Pharmacology

View Paper: https://www.semanticscholar.org/paper/ab844f67eab574790b181e6add7c738cf061dba8